Compare Diamondback Energy Inc (FANG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs GeneDx Holdings Corp — how do they compare? Diamondback Energy Inc trades at $192.03 (market cap $53.67B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Diamondback Energy Inc is far larger — about 26.6× GeneDx Holdings Corp's market cap, and Diamondback Energy Inc pays a 2.3% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and GeneDx Holdings Corp for 19 Days on average.
| FANG | WGS | |
|---|---|---|
Market Cap | $53.67B | $2.02B |
Volume | 2,250,644 | 734,640 |
Sector | Energy | Health |
52-Week High | $213.69 | $167.51 |
52-Week Low | $137.29 | $34.51 |
Typical Hold Time | 69 Days | 19 Days |
Enterprise Value | $65.83B | $2.05B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $192.13, up 4.2% in the last session, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains solid cash flow from operations. Revenue growth is robust, with 2025 revenue reaching $14.93 billion, though net income margins have compressed. A dividend of $1.10 is scheduled for August 2026, and institutional interest remains high.
The outlook is positive with a consensus price target of $231.77, implying 20% upside. Risks include volatile oil prices and insider selling, but strong Permian Basin positioning and efficient operations support growth. Earnings on November 2, 2026, will be critical for near-term momentum.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
